Copyright © 2012 Katja Simon-Keller et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

1. G. P. Dunn, A. T. Bruce, H. Ikeda, L. J. Old, and R. D. Schreiber, “Cancer immunoediting: from immunosurveillance to tumor escape,” Nature Immunology, vol. 3, no. 11, pp. 991–998, 2002. View at Publisher · View at Google Scholar · View at Scopus
2. G. P. Dunn, H. Ikeda, A. T. Bruce et al., “Interferon-γ and cancer immunoediting,” Immunologic Research, vol. 32, no. 1-3, pp. 231–245, 2005. View at Publisher · View at Google Scholar · View at Scopus
3. H. Ikeda, L. J. Old, and R. D. Schreiber, “The roles of IFNγ in protection against tumor development and cancer immunoediting,” Cytokine and Growth Factor Reviews, vol. 13, no. 2, pp. 95–109, 2002. View at Publisher · View at Google Scholar · View at Scopus
4. L. Wall, F. Burke, C. Barton, J. Smyth, and F. Balkwill, “IFN-γ induces apoptosis in ovarian cancer cells in vivo and in vitro,” Clinical Cancer Research, vol. 9, no. 7, pp. 2487–2496, 2003. View at Scopus
5. M. C. Zhang, H. P. Liu, L. L. Demchik, Y. F. Zhai, and D. J. Yang, “LIGHT sensitizes IFNγ-mediated apoptosis of HT-29 human carcinoma cells through both death receptor and mitochondria pathways,” Cell Research, vol. 14, no. 2, pp. 117–124, 2004. View at Publisher · View at Google Scholar · View at Scopus
6. T. Toyonaga, O. Hino, S. Sugai et al., “Chronic active hepatitis in transgenic mice expressing interferon-γ in the liver,” Proceedings of the National Academy of Sciences of the United States of America, vol. 91, no. 2, pp. 614–618, 1994. View at Scopus
7. M. Moreno, J. W. Molling, S. Von Mensdorff-Pouilly et al., “IFN-γ-producing human invariant NKT cells promote tumor-associated antigen-specific cytotoxic T cell responses,” Journal of Immunology, vol. 181, no. 4, pp. 2446–2454, 2008. View at Scopus
8. J. R. Schoenborn and C. B. Wilson, “Regulation of interferon-γ during innate and adaptive immune responses,” Advances in Immunology, vol. 96, pp. 41–101, 2007. View at Publisher · View at Google Scholar · View at Scopus
9. B. Saha, S. Jyothi Prasanna, B. Chandrasekar, and D. Nandi, “Gene modulation and immunoregulatory roles of Interferonγ,” Cytokine, vol. 50, no. 1, pp. 1–14, 2010. View at Publisher · View at Google Scholar · View at Scopus
10. K. Schroder, P. J. Hertzog, T. Ravasi, and D. A. Hume, “Interferon-γ: an overview of signals, mechanisms and functions,” Journal of Leukocyte Biology, vol. 75, no. 2, pp. 163–189, 2004. View at Publisher · View at Google Scholar · View at Scopus
11. I. M. Kerr, A. P. Costa-Pereira, B. F. Lillemeier, and B. Strobl, “Of JAKs, STATs, blind watchmakers, jeeps and trains,” FEBS Letters, vol. 546, no. 1, pp. 1–5, 2003. View at Publisher · View at Google Scholar · View at Scopus
12. B. Chen, L. He, V. H. Savell, J. J. Jenkins, and D. M. Parham, “Inhibition of the interferon-γ/signal transducers and activators of transcription (STAT) pathway by hypermethylation at a STAT-binding site in the p21(WAF1) promoter region,” Cancer Research, vol. 60, no. 12, pp. 3290–3298, 2000. View at Scopus
13. E. B. Burova, I. S. Smirnova, I. V. Gonchar, A. N. Shatrova, and N. N. Nikolsky, “Inhibition of the EGF receptor and ERK1/2 signaling pathways rescues the human epidermoid carcinoma A431 cells from IFNγ-induced apoptosis,” Cell Cycle, vol. 10, no. 13, pp. 2197–2205, 2011. View at Publisher · View at Google Scholar · View at Scopus
14. H. Nguyen, C. V. Ramana, J. Bayes, and G. R. Stark, “Roles of phosphatidylinositol 3-kinase in interferon-γ-dependent phosphorylation of STAT1 on serine 727 and activation of gene expression,” Journal of Biological Chemistry, vol. 276, no. 36, pp. 33361–33368, 2001. View at Publisher · View at Google Scholar · View at Scopus
15. G. G. Choudhury, “A linear signal transduction pathway involving phosphatidylinositol 3-kinase, protein kinase Cε, and MAPK in mesangial cells regulates interferon-γ-induced STAT1α transcriptional activation,” Journal of Biological Chemistry, vol. 279, no. 26, pp. 27399–27409, 2004. View at Publisher · View at Google Scholar · View at Scopus
16. Y. A. Mebratu, B. F. Dickey, C. Evans, and Y. Tesfaigzi, “The BH3-only protein BikJBlkJNbk inhibits nuclear translocation of activated ERK1J2 to mediate IFNγ-induced cell death,” Journal of Cell Biology, vol. 183, no. 3, pp. 429–439, 2008. View at Publisher · View at Google Scholar · View at Scopus
17. S. Gallego Melcón and J. Sánchez de Toledo Codina, “Molecular biology of rhabdomyosarcoma,” Clinical and Translational Oncology, vol. 9, no. 7, pp. 415–419, 2007. View at Publisher · View at Google Scholar · View at Scopus
18. A. Ferrari, I. Sultan, T. T. Huang et al., “Soft tissue sarcoma across the age spectrum: a population-based study from the surveillance epidemiology and end results database,” Pediatric Blood and Cancer, vol. 57, no. 6, pp. 943–949, 2011. View at Publisher · View at Google Scholar
19. W. M. Crist, J. R. Anderson, J. L. Meza et al., “Intergroup Rhabdomyosarcoma Study-IV: results for patients with nonmetastatic disease,” Journal of Clinical Oncology, vol. 19, no. 12, pp. 3091–3102, 2001. View at Scopus
20. T. M. Dantonello, C. Int-Veen, D. Harms et al., “Cooperative trial CWS-91 for localized soft tissue sarcoma in children, adolescents, and young adults,” Journal of Clinical Oncology, vol. 27, no. 9, pp. 1446–1455, 2009. View at Publisher · View at Google Scholar · View at Scopus
21. S. Gattenlöhner, H. K. Müller-Hermelink, and A. Marx, “Polymerase chain reaction-based diagnosis of rhabdomyosarcomas: comparison of fetal type acetylcholine receptor subunits and myogenin,” Diagnostic Molecular Pathology, vol. 7, no. 3, pp. 129–134, 1998. View at Publisher · View at Google Scholar · View at Scopus
22. K. Simon-Keller, A. Paschen, S. Eichmüller et al., “Adoptive T-cell therapy of rhabdomyosarcoma,” Der Pathologe, vol. 31, pp. 215–220, 2010. View at Scopus
23. S. Gattenlöhner, A. Marx, B. Markfort et al., “Rhabdomyosarcoma lysis by T cells expressing a human autoantibody-based chimeric receptor targeting the fetal acetylcholine receptor,” Cancer Research, vol. 66, no. 1, pp. 24–28, 2006. View at Publisher · View at Google Scholar · View at Scopus
24. S. Poëa-Guyon, P. Christadoss, R. Le Panse et al., “Effects of cytokines on acetylcholine receptor expression: implications for myasthenia gravis,” Journal of Immunology, vol. 174, no. 10, pp. 5941–5949, 2005. View at Scopus
25. D. Schuhmann, P. Godoy, C. Weiß et al., “Interfering with interferon-γ signalling in intestinal epithelial cells: selective inhibition of apoptosis-maintained secretion of anti-inflammatory interleukin-18 binding protein,” Clinical and Experimental Immunology, vol. 163, no. 1, pp. 65–76, 2011. View at Publisher · View at Google Scholar · View at Scopus
26. M. A. Farrar and R. D. Schreiber, “The molecular cell biology of interferon-γ and its receptor,” Annual Review of Immunology, vol. 11, pp. 571–611, 1993. View at Scopus
27. B. Chen, L. He, V. H. Savell, J. J. Jenkins, and D. M. Parham, “Inhibition of the interferon-γ/signal transducers and activators of transcription (STAT) pathway by hypermethylation at a STAT-binding site in the p21(WAF1) promoter region,” Cancer Research, vol. 60, no. 12, pp. 3290–3298, 2000. View at Scopus
28. P. Bernabei, E. M. Coccia, L. Rigamonti et al., “Interferon-γ receptor 2 expression as the deciding factor in human T, B, and myeloid cell proliferation or death,” Journal of Leukocyte Biology, vol. 70, no. 6, pp. 950–960, 2001. View at Scopus
29. I. Sadzak, M. Schiff, I. Gattermeier et al., “Recruitment of Stat1 to chromatin is required for interferon-induced serine phosphorylation of Stat1 transactivation domain,” Proceedings of the National Academy of Sciences of the United States of America, vol. 105, no. 26, pp. 8944–8949, 2008. View at Publisher · View at Google Scholar · View at Scopus
30. K. M. McBride, G. Banninger, C. McDonald, and N. C. Reich, “Regulated nuclear import of the STAT1 transcription factor by direct binding of importin-α,” EMBO Journal, vol. 21, no. 7, pp. 1754–1763, 2002. View at Publisher · View at Google Scholar · View at Scopus
31. N. Van Der Stoep, P. Biesta, E. Quinten, and P. J. Van Den Elsen, “Lack of IFN-γ-mediated induction of the class II transactivator (CIITA) through promoter methylation is predominantly found in developmental tumor cell lines,” International Journal of Cancer, vol. 97, no. 4, pp. 501–507, 2002. View at Publisher · View at Google Scholar · View at Scopus
32. P. Londhe, B. Zhu, J. Abraham, C. Keller, and J. Davie, “CIITA is silenced by epigenetic mechanisms that prevent the recruitment of transactivating factors in rhabdomyosarcoma cells,” International Journal of Cancer, vol. 131, no. 4, pp. E437–E448, 2012. View at Publisher · View at Google Scholar · View at Scopus
33. G. Hu, A. Y. Gong, J. Liu, R. Zhou, C. Deng, and X. M. Chen, “miR-221 suppresses ICAM-1 translation and regulates interferon-γ- induced ICAM-1 expression in human cholangiocytes,” American Journal of Physiology, vol. 298, no. 4, pp. G542–G550, 2010. View at Publisher · View at Google Scholar · View at Scopus
34. A. S. Dighe, E. Richards, L. J. Old, and R. D. Schreiber, “Enhanced in vivo growth and resistance to rejection of tumor cells expressing dominant negative IFNγ receptors,” Immunity, vol. 1, no. 6, pp. 447–456, 1994. View at Scopus
35. D. H. Kaplan, V. Shankaran, A. S. Dighe et al., “Demonstration of an interferon γ-dependent tumor surveillance system in immunocompetent mice,” Proceedings of the National Academy of Sciences of the United States of America, vol. 95, no. 13, pp. 7556–7561, 1998. View at Publisher · View at Google Scholar · View at Scopus
36. G. P. Dunn, C. M. Koebel, and R. D. Schreiber, “Interferons, immunity and cancer immunoediting,” Nature Reviews Immunology, vol. 6, no. 11, pp. 836–848, 2006. View at Publisher · View at Google Scholar · View at Scopus